Want to join the conversation?
$REGN 2Q15 Call: Has 15 antibodies that are in clinical development and has late-stage programs in five different therapeutic areas; Sarilumab for rheumatoid arthritis; Dupilumab for atopic dermatitis and asthma; Fasinumab for pain; and REGN2222 for respiratory syncytial virus.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?